Tarsus Pharmaceuticals to acquire Alkeus Pharmaceuticals for up to $800 million

Tarsus Pharmaceuticals Inc. has agreed to acquire privately held Alkeus Pharmaceuticals Inc. for up to approximately $800 million. Alkeus is a clinical-stage biopharmaceutical company developing retinal therapies. The acquisition expands Tarsus's pipeline in the retinal therapies space. Tarsus is based in Irvine, California.